Development of CD33-Targeted Dual Drug-Loaded Nanoparticles for the Treatment of Pediatric Acute Myeloid Leukemia
Biomacromolecules · 2024
DOI: 10.1021/acs.biomac.4c00672 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomacromolecules, 2024. Verfasst von Ana M Carvalho und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Patrick G Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast BT9 7AE…. Hauptthemen laut MEDLINE: Sialic Acid Binding Ig-like Lectin 3, Leukemia, Myeloid, Acute, Nanoparticles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Children's Cancer and Leukaemia Group, Horizon 2020 Framework Programme.
Abstract (Originalsprache)
Paediatric acute myeloid leukemia (AML) is a heterogeneous hematological malignancy still heavily reliant on traditional chemotherapeutic approaches. Combination treatments have shown to be a superior approach, but their success is often hindered by side effects and different drugs' pharmacokinetics. Here, we investigated ABT-737 and Purvalanol A as a potential drug pairing for pediatric AML and described the development of CD33-targeted polymeric nanoparticles (NPs) to enable their simultaneous targeted codelivery. Separate drug encapsulation within poly(lactic-co-glycolic acid) (PLGA) NPs was optimized prior to coencapsulation of both drugs at a synergistic ratio in PEGylated PLGA NPs. The therapeutic effects of formulations were evaluated in a panel of pediatric AML cells, and dual drug-loaded NPs (dual NPs) demonstrated significantly enhanced apoptotic cell death. Moreover, conjugation to gemtuzumab resulted in improved NP binding and internalization in CD33-positive cells. Finally, CD33-targeted dual-loaded NPs showed enhanced cytotoxicity to CD33-positive AML cells via CD33-mediated targeted drug delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Patrick G Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast BT9 7AE, U.K.
ORCID-Profile: Christopher J Scott
Förderung
- Children's Cancer and Leukaemia Group
- Horizon 2020 Framework Programme
Zitieren
APA
Carvalho, A. M., Greene, M. K., Smyth, P., Mutch, A., McLaughlin, K. M., Cairns, L. V., Mills, K. I., McCloskey, K. D., & Scott, C. J. (2024). Development of CD33-Targeted Dual Drug-Loaded Nanoparticles for the Treatment of Pediatric Acute Myeloid Leukemia. Biomacromolecules. https://doi.org/10.1021/acs.biomac.4c00672
Vancouver
Carvalho AM, Greene MK, Smyth P, Mutch A, McLaughlin KM, Cairns LV, et al. Development of CD33-Targeted Dual Drug-Loaded Nanoparticles for the Treatment of Pediatric Acute Myeloid Leukemia. Biomacromolecules. 2024. doi:10.1021/acs.biomac.4c00672
BibTeX
@article{Carvalho2024,
author = {Carvalho, Ana M and Greene, Michelle K and Smyth, Peter and Mutch, Alexander and McLaughlin, Kirsty M and Cairns, Lauren V and Mills, Ken I and McCloskey, Karen D and Scott, Christopher J},
title = {Development of CD33-Targeted Dual Drug-Loaded Nanoparticles for the Treatment of Pediatric Acute Myeloid Leukemia},
journal = {Biomacromolecules},
year = {2024},
doi = {10.1021/acs.biomac.4c00672}
}
EUVIMED